Easy Bio KRX:353810KOSDAQ
이지바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked1since Sep 11
In Q2 2026, Easy Bio reported revenue of ₩148bn, up 30.2% year on year, and operating profit of ₩15.1bn. Easy Bio (이지바이오) appeared in 0 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 19 with 1 article.
Filing signals Revenue +30% Revenue & profit growth Dividend grower Major holder adding Screener
Easy Bio quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩148bn | +30.2% | ₩15.1bn margin 10.2% | ₩10.9bn |
| Q1 2026 | ₩131bn | +11.8% | ₩13.2bn margin 10.1% | ₩11.7bn |
| Q4 2025 derived | ₩129bn | +9.9% | ₩13.6bn margin 10.5% | ₩10.8bn |
| Q3 2025 | ₩117bn | +9.8% | ₩11.2bn margin 9.6% | ₩8.6bn |
| Q2 2025 | ₩114bn | +12.8% | ₩11.0bn margin 9.7% | ₩4.1bn |
| Q1 2025 | ₩117bn | +96.8% | ₩9.1bn margin 7.8% | ₩5.8bn |
| Q4 2024 derived | ₩118bn | +176.2% | ₩8.7bn margin 7.4% | ₩4.6bn |
| Q3 2024 | ₩106bn | +149.4% | ₩8.9bn margin 8.4% | ₩6.3bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Easy Bio top stories 2 weeks, by number of outlets
- 1